Asian Cancer Research Group

The Asian Cancer Research Group, led by Pfizer, Eli Lilly, and Merck, has used whole-genome sequencing to identify recurrent, druggable mutations in hepatocellular carcinoma.

NEW YORK (GenomeWeb News) – A pair of studies in the early, online version of Nature Genetics are highlighting the types of genetic mutations that underlie the liver cancer hepatocellular carcinoma, including forms of the disease related to hepatitis B and hepatitis C virus infection.

Recently, Mao Mao, a research fellow at Pfizer Oncology Research who is working on several different cancer sequencing projects, spoke to In Sequence about the company's use of sequencing in drug development and the hurdles that still remain in implementing the technology in pharmaceutical research.

Through the formation of the Asian Cancer Research Group, Eli Lily, Merck, and Pfizer have also committed "to create one of the most extensive pharmacogenomic cancer databases known to date."

The Associated Press reports that gene-edited food may soon be for sale.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.